newsfilter
← Latest News
GlobeNewswire·

Turning Point Therapeutics Presents Early Clinical Data for Repotrectinib From Care Study in Pediatric and Young Adult Patients at SIOP 2021 Virtual Congress

Early Clinical Activity and Safety Profile Support Continued Investigation of Repotrectinib in Pediatric Tumors Harboring ALK, ROS1 or NTRK Alterations Repotrectinib Demonstrated Confirmed Responses in 3 of 4 TKI-Naïve Patients SAN DIEGO, Oct.